2026年11月11日至15日,由中国抗癌协会主办,国际整体整合医学学会、世界整合肿瘤学会、湖南省抗癌协会共同主办,湖南省肿瘤医院承办的2026中国整合肿瘤学大会(CCHIO)在湖南长沙召开。伴随精准肿瘤学的持续渗透,联合治疗已成为突破单药疗效瓶颈、应对肿瘤异质性的重要路径,但其方案设计逻辑与临床转化路径仍存在诸多待解的行业难题。会议期间,《肿瘤瞭望》特邀美国癌症研究协会(AACR)现任主席Keith Flaherty教授接受专访,从技术发展、方案设计、研发策略、国际协作四大维度,分享他对肿瘤联合治疗发展的深度思考。
编者按:2026年11月11日至15日,由中国抗癌协会主办,国际整体整合医学学会、世界整合肿瘤学会、湖南省抗癌协会共同主办,湖南省肿瘤医院承办的2026中国整合肿瘤学大会(CCHIO)在湖南长沙召开。伴随精准肿瘤学的持续渗透,联合治疗已成为突破单药疗效瓶颈、应对肿瘤异质性的重要路径,但其方案设计逻辑与临床转化路径仍存在诸多待解的行业难题。会议期间,《肿瘤瞭望》特邀美国癌症研究协会(AACR)现任主席Keith Flaherty教授接受专访,从技术发展、方案设计、研发策略、国际协作四大维度,分享他对肿瘤联合治疗发展的深度思考。
《肿瘤瞭望》:Flaherty教授,您本次演讲的主题是“Accelerating the Development of Rational Combinations Therapies for Cancer”。随着肿瘤治疗进入精准治疗时代,“联合治疗”迎来了怎样的发展与挑战?
Keith Flaherty 教授:推动联合治疗向前发展的最大机遇,源于近5到10年间肿瘤分子表征技术的快速进步。长期以来,我们以基因突变或基因变异的检测结果为基础,搭建了第一代精准肿瘤学的框架,但肿瘤的复杂程度远远超出了基因层面所能揭示的范畴。
以已成为临床标准方案十余年的肿瘤免疫治疗为例,想要实现更精准的应用,无法仅靠单一的肿瘤分子特征来匹配患者,必须建立更全面的肿瘤特征认知。只有跳出单纯的DNA突变测序,拓展应用更多维度的分子检测技术,我们才能充分挖掘现有治疗手段的联合应用价值,也才能为下一代创新疗法的联合布局打下基础。
《肿瘤瞭望》:在设计合理联合治疗方案时,如何判断哪些方案真正能够使患者从联合治疗中获益?如何发掘这些决策因素?
Keith Flaherty 教授:当前我们面临的明显局限是,仅依靠单一技术平台的分子检测,很难为多数患者筛选出合适的联合方案。比如仅通过突变检测,仅能为2%~3%的肿瘤患者提示两药联合的方向,因此我们必须转向多模态的分子表征思路。
RNA表达测序作为研究手段已有二十余年历史,但始终未被充分转化为精准医学的常规分析工具。现有大量研究证据显示,肿瘤细胞的转录组信息能够更有效地指导单药治疗,也能为联合方案的筛选提供依据。而在此之外,基于人工智能技术的数字病理图像分析,可以提取到比DNA、RNA测序更丰富的肿瘤生物学特征,这将是未来实现联合治疗精准化应用的必要工具。
《肿瘤瞭望》:随着创新药的不断涌现,联合方案的组合种类繁多。从早期临床研究到后续确证性研究,您认为加速合理联合治疗开发最需要解决哪些关键问题?
Keith Flaherty 教授:首先要突破的是静态分子检测的局限性。目前常用的分子诊断工具,本质上只是捕捉了肿瘤细胞某一个时间点的状态快照,不足以完整反映肿瘤真实的治疗敏感性。活细胞体外检测技术(离体功能诊断)可在体外层面验证药物敏感性,能够对静态分子检测形成有效补充,但这一领域目前尚不成熟,无论是研究方法还是临床应用都处于早期阶段,需要投入更多资源与精力验证其实际价值。
除此以外,肿瘤的异质性与复杂性也是一大难题。我们需要调整研究策略,在肿瘤演化的更早阶段测试治疗方案。循环肿瘤DNA等血液检测技术提供了契机:我们可以识别出那些接受了手术、放疗等根治性治疗后,影像学无法发现病灶、但血液中可检测到循环肿瘤DNA(分子残留病灶)的患者,在这一疾病阶段更早地测试新疗法乃至联合方案。相比多线治疗后的复发转移人群,早期阶段的肿瘤复杂性更低,能帮助我们更快探索出有效的治疗方案。
《肿瘤瞭望》:CACA与AACR近年来不断深化合作。作为AACR现任主席,您期待双方未来在哪些领域进一步加强协作,共同推动肿瘤研究和临床转化?
Keith Flaherty 教授:肿瘤的复杂性不仅体现在单个患者的病灶中,也体现在全球不同人群的肿瘤谱差异里。不同人群的祖先背景、胚系遗传特征、特有的环境暴露因素,都会影响个体的肿瘤发生风险与肿瘤的分子特征,而目前我们对这些人群层面的差异与共性仍缺乏系统性的基础认知。
美国癌症研究协会(AACR)与中国抗癌协会(CACA)分别依托中美两大成熟的肿瘤诊疗与研究体系,双方有极大的合作空间。我们可以共同搭建研究框架,解析不同人群肿瘤特征的异同与背后的分子机制,最终将这些认知转化为治疗方案的开发与临床应用。这一合作不仅能解决双方共同的临床问题,也将为搭建全球性的肿瘤转化研究平台奠定基础,共同应对肿瘤这一全球公共卫生议题。
Oncology Frontier: Professor Flaherty, your presentation is titled “Accelerating the Development of Rational Combination Therapies for Cancer”. As cancer treatment enters the era of precision medicine, what new opportunities and challenges does combination therapy face?
Professor Keith Flaherty: The greatest opportunity driving combination therapy forward comes from the rapid advances in tumor molecular characterization technologies over the past 5 to 10 years. For a long time, we built the framework of first-generation precision oncology based on detected gene mutations or genetic alterations, but the complexity of tumors extends far beyond what can be uncovered at the genetic level.
Take cancer immunotherapy, which has been a standard of care for over a decade, as an example. To deliver it more precisely, we cannot match patients based on a single molecular feature of their tumor alone; a more comprehensive understanding of tumor biology is required. Only by moving beyond standalone DNA mutation sequencing and expanding the use of multi-dimensional molecular detection technologies can we fully unlock the combined potential of existing treatments, and lay the groundwork for deploying next-generation innovative therapies in combination.
Oncology Frontier: When designing rational combination therapy regimens, how can we identify which combinations will truly benefit patients? How can we identify the factors that guide these decisions?
Professor Keith Flaherty: A clear limitation today is that molecular detection relying on a single technical platform can rarely identify suitable combination regimens for most patients. For instance, mutation detection alone can point to a two-drug combination for only 2% to 3% of patients with cancer. For this reason, we must adopt a multimodal approach to molecular characterization.
RNA expression analysis has served as a research method for more than two decades, yet it has not been fully translated into a routine analytical tool for precision medicine practice. A large body of published evidence indicates that the transcriptomic information of tumor cells can guide not only single-agent use but also the selection of combination regimens more effectively. Going further, AI-powered digital pathology image analysis can capture even more tumor biological features than DNA and RNA sequencing, and will be an essential tool for realizing precise delivery of combination therapy in the future.
Oncology Frontier: With a growing number of innovative drugs coming onto the scene, the possible combinations of treatment regimens have multiplied. From early-phase trials to confirmatory studies, what key issues must be resolved to accelerate the development of rational combination therapies?
Professor Keith Flaherty: The first barrier to break through is the limitation of static molecular detection. Current molecular diagnostic tools essentially capture only a snapshot of tumor cell status at a single time point, which is insufficient to fully reflect the true therapeutic sensitivity of tumors. Ex vivo functional testing of live tumor cells can test drug sensitivity outside the patient body and complement static molecular testing. However, this field is still immature; both its research methodologies and clinical application are in the early stages, requiring greater investment of resources and effort to verify its practical value.
Beyond that, tumor heterogeneity and complexity pose another major challenge. We need to adjust our research strategy and test therapeutic regimens at an earlier stage of tumor evolution. Blood-based detection technologies, particularly circulating tumor DNA assays, open up this possibility. We can identify patients who have received definitive local therapy such as surgery or radiotherapy, with no lesions visible on radiographic imaging but detectable circulating tumor DNA (molecular residual disease) in the blood. Testing new therapies and even combination regimens in this earlier disease setting, rather than in patients with recurrent metastatic disease who have received multiple lines of prior therapy, will allow us to identify effective new regimens much faster, when the tumor is far less complex.
Oncology Frontier: CACA and AACR have deepened their collaboration in recent years. As the current AACR President, in which areas would you like to see the two organizations strengthen their partnership to jointly advance cancer research and clinical translation?
Professor Keith Flaherty: The complexity of cancer exists not only within an individual patient’s tumor, but also across the cancer spectra of different populations worldwide. Ancestral background, germline genetic variation and population-specific environmental exposures all shape an individual’s cancer risk and the molecular profile of their tumors. At present, we still lack a systematic, foundational understanding of the differences and similarities across populations in this regard.
The American Association for Cancer Research and the Chinese Anti-Cancer Association represent two large, well-established cancer care and research systems, and there is enormous potential for collaboration between them. We can jointly build a research framework to characterize the similarities and differences in cancer populations and their underlying molecular mechanisms, and ultimately translate these insights into the development and delivery of therapeutic regimens. This is ultimately a global challenge, and our partnership can set the stage for a global translational research platform of this kind.
Keith T. Flaherty
现任AACR主席
麻省总医院癌症中心临床肿瘤研究主任
Richard Saltonstall 肿瘤学讲席教授
哈佛医学院医学教授
麻省理工-哈佛 Broad 研究所副成员